Castle Biosciences, Inc. announced new data showing the TissueCypher Barrett’s Esophagus test can provide risk insights beyond pathology alone. The test influences clinical management, supporting earlier intervention for those at higher risk of progression to esophageal cancer. The findings will be presented at the ACG 2025 Annual Scientific Meeting. The test has been shown to deliver valuable insights that help reduce the risk of mortality from esophageal adenocarcinoma. The TissueCypher test aims to transform disease management by guiding patient care and informing more personalized decisions around surveillance and intervention.

The Tissue Systems Pathology Test (TSP-9) has shown to inform management of patients with Barrett’s esophagus, providing insights that help predict progression to high-grade dysplasia or esophageal adenocarcinoma. The test has been able to identify patients at high risk who may otherwise be missed, enabling clinicians to act sooner and potentially reduce the risk of progression to cancer. The test has received recognition at the ACG 2025 Annual Scientific Meeting for its unique and novel research findings. Castle Biosciences aims to keep patients first by improving health through innovative tests that guide patient care.

Read more at GlobeNewswire: New Data at American College of Gastroenterology Annual